PLIANT THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $— | $— |
| Operating expenses: | ||
| Research and development | (109,157) | (169,310) |
| General and administrative | (47,216) | (59,055) |
| Total operating expenses | (156,373) | (228,365) |
| Loss from operations | (156,373) | (228,365) |
| Interest and other income (expense), net | 11,416 | 21,085 |
| Interest expense | (2,559) | (3,024) |
| Loss on extinguishment of debt (Note 7) | (1,828) | — |
| Net loss | $(149,344) | $(210,304) |
| Net loss per share - basic and diluted | $(2.43) | $(3.47) |
| Weighted average shares used in computing net loss per share - basic and diluted | 61,366,887 | 60,538,639 |
| Comprehensive loss: | ||
| Net loss | $(149,344) | $(210,304) |
| Net unrealized loss on short-term investments | (336) | (24) |
| Total other comprehensive loss | (336) | (24) |
| Comprehensive loss | $(149,680) | $(210,328) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.